Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.

Détails

ID Serval
serval:BIB_35AE485BF889
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016.
Périodique
Modern pathology
Auteur⸱e⸱s
Lugli A., Kirsch R., Ajioka Y., Bosman F., Cathomas G., Dawson H., El Zimaity H., Fléjou J.F., Hansen T.P., Hartmann A., Kakar S., Langner C., Nagtegaal I., Puppa G., Riddell R., Ristimäki A., Sheahan K., Smyrk T., Sugihara K., Terris B., Ueno H., Vieth M., Zlobec I., Quirke P.
ISSN
1530-0285 (Electronic)
ISSN-L
0893-3952
Statut éditorial
Publié
Date de publication
09/2017
Peer-reviewed
Oui
Volume
30
Numéro
9
Pages
1299-1311
Langue
anglais
Notes
Publication types: Consensus Development Conference ; Journal Article ; Practice Guideline ; Review
Publication Status: ppublish
Résumé
Tumor budding is a well-established independent prognostic factor in colorectal cancer but a standardized method for its assessment has been lacking. The primary aim of the International Tumor Budding Consensus Conference (ITBCC) was to reach agreement on an international, evidence-based standardized scoring system for tumor budding in colorectal cancer. The ITBCC included nine sessions with presentations, a pre-meeting survey and an e-book covering the key publications on tumor budding in colorectal cancer. The 'Grading of Recommendation Assessment, Development and Evaluation' method was used to determine the strength of recommendations and quality of evidence. The following 10 statements achieved consensus: tumor budding is defined as a single tumor cell or a cell cluster consisting of four tumor cells or less (22/22, 100%). Tumor budding is an independent predictor of lymph node metastases in pT1 colorectal cancer (23/23, 100%). Tumor budding is an independent predictor of survival in stage II colorectal cancer (23/23, 100%). Tumor budding should be taken into account along with other clinicopathological features in a multidisciplinary setting (23/23, 100%). Tumor budding is counted on H&E (19/22, 86%). Intratumoral budding exists in colorectal cancer and has been shown to be related to lymph node metastasis (22/22, 100%). Tumor budding is assessed in one hotspot (in a field measuring 0.785 mm <sup>2</sup> ) at the invasive front (22/22, 100%). A three-tier system should be used along with the budding count in order to facilitate risk stratification in colorectal cancer (23/23, 100%). Tumor budding and tumor grade are not the same (23/23, 100%). Tumor budding should be included in guidelines/protocols for colorectal cancer reporting (23/23, 100%). Members of the ITBCC were able to reach strong consensus on a single international, evidence-based method for tumor budding assessment and reporting. It is proposed that this method be incorporated into colorectal cancer guidelines/protocols and staging systems.
Mots-clé
Biopsy/standards, Cell Movement, Colorectal Neoplasms/mortality, Colorectal Neoplasms/pathology, Colorectal Neoplasms/therapy, Consensus, Humans, Lymphatic Metastasis, Neoplasm Invasiveness, Neoplasm Staging, Pathology, Clinical/standards, Predictive Value of Tests
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/09/2017 16:57
Dernière modification de la notice
20/08/2019 13:23
Données d'usage